Like for many multifactorial and chronic diseases,2 it is critical to offer both pharmacological and non-pharmacological options to your employees with obesity, as one specific strategy will not address the needs of everyone in your organization.3
Get 3 learning modules to learn about your next action steps for optimizing coverage for weight-loss treatments, including AOMs.
People with obesity have reason to be concerned about COVID-19 based on the increased risks they face. This resource discusses these risks and provides information on COVID-19 and obesity.
References: 1. Nobel J, Pickering L, Sasser E. Tipping the Scales on Weight Control: New Strategies for Employers. https://nebgh.org/wp-content/uploads/2016/08/NEBGH_Tipping-the-Scales-2016.pdf. Published August 2016. Accessed January 3, 2021. 2. Mechanick JI, Garber AJ, Handelsman Y, Garvey WT. American Association of Clinical Endocrinologists’ position statement on obesity and obesity medicine. Endocr Pract. 2012;18(5):642-648. 3. Wadden TA, Berkowitz Rl, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353(20):2111-2120. 4. Garvey WT, Mechanick JI, Brett EM, et al. Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(suppl 3):1-203.